Nano-miR-133a Replacement Therapy Blunts Pressure Overload-Induced Heart Failure

Circulation. 2021 Dec 14;144(24):1973-1976. doi: 10.1161/CIRCULATIONAHA.121.055866. Epub 2021 Dec 13.

Jessica Modica^#^{1

2}, Vittoria Di Mauro^#^{1

3}, Maria Barandalla-Sobrados^{1

3}, Samuel Elias Pineda Chavez^{3

4}, Pierluigi Carullo^{1

3}, Simona Nemska³, Achille Anselmo³, Gianluigi Condorelli^{1

2}, Michele Iafisco⁵, Michele Miragoli^{1

3

4}, Daniele Catalucci^{1

3}

¹ National Research Council-Institute of Genetics and Biomedical Research, Milan Unit, Italy (J.M., V.D.M., M.B.-S., P.C., G.C., M.M., D.C.).
² Humanitas University, Pieve Emanuele (Milan), Italy (G.C., J.M.).
³ IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy (V.D.M., M.B.-S., S.E.P.C., P.C., S.N., A.A., M.M., D.C.).
⁴ Department of Medicine and Surgery, University of Parma, Italy (S.E.P.C., M.M.).
⁵ National Research Council-Institute of Science & Technology for Ceramics, Faenza, Italy (M.I.).

^# Contributed equally.

No abstract available

Keywords: RNA; cardiomyocytes; heart failure; inhalation; microRNAs; nanoparticles; therapeutics.

Publication types